The latest from CDMOs, CMOs, and suppliers featuring Eurofins CDMO Alphora, Cambrex, Ascend Advanced Therapies, Just-Evotec Biologics, Pace Life Sciences, Verdot and ten23 health.  

Chemicals/Chemical API Manufacturing 
* Cambrex, Atinary Technologies in AI Pact for Process Optimization 
Biologics Manufacturing 
* Eurofins CDMO Alphora Investing $64 M in New Biologics Mfg Facility  
* Just-Evotec Biologics Opens Modular Biomanufacturing Facility
* Ascend Advanced Therapies Expanding Viral Vector Mfg 
* Verdot To Build New HQ & Mfg Facility for Downstream Bioprocessing Systems  
Formulation Development/Drug Product Manufacturing 
* Thermo Fisher Expands Oral Solid Dosage Ops at US Sites  
* Ten23 Health Opens New Fill-Finish Facility 
General 
* Pace Life Sciences Acquires Catalent’s Center of Excellence for Small-Molecule Analytics 

---

Chemicals/Chemical API Manufacturing 

Cambrex, Atinary Technologies in AI Pact for Process Optimization 
Snapdragon Chemistry, a Cambrex company, and Atinary Technologies, a company specializing in artificial intelligence (AI)-based platforms for process optimization, have announced a strategic collaboration using Atinary’s AI platform to optimize active pharmaceutical ingredient (API) process development.  Snapdragon Chemistry focuses on API process development, with a specialization in continuous flow process development, lab automation, and complex synthetic APIs.

Through this collaboration, Snapdragon integrated its LabOS software platform with Atinary’s SDLabs platform to build a fully automated and AI-driven, medium-throughput solid-phase oligonucleotide synthesizer for the purpose of autonomous multi-objective process optimization.  

Source: Cambrex 

---

Biologics Manufacturing 

Eurofins CDMO Alphora Investing $64 M in New Biologics Mfg Facility 
Eurofins CDMO Alphora, a Mississauga, Ontario, Canada-based CDMO of drug substances and drug products, has announced plans to construct a new $64-million GMP biologics manufacturing facility in Mississauga, for producing monoclonal antibodies and protein therapies for clinical and commercial applications. 

The 50,000-square-foot biologics manufacturing facility, scheduled for completion in April 2026, will be housed within a new 112,000-square-foot building, constructed on Eurofins CDMO Alphora’s 14-acre campus in Mississauga. The facility will be equipped to the 2,000-L bioreactor scale, employ single-use technology, and be capable of running both fed-batch and perfusion modes. It will provide a fully integrated offering with a sterile fill line with a capacity of up to 24.9 million units annually. 

This investment follows the completion of Eurofins CDMO Alphora’s biologics development and pilot-scale facility, which has been operational since January 2024. 

Source: Eurofins CDMO Alphora 

---

Just-Evotec Biologics Opens Modular Biomanufacturing Facility 
Just – Evotec Biologics, the biologics segment of Evotec, has opened a new modular biologics development and manufacturing facility in Toulouse, France. The 15,000-square-meter facility provides clinical and commercial biologics manufacturing capacity and uses the company’s J.POD technology for modular and continuous biomanufacturing. 

Source: Just-Evotec Biologics 

---

Ascend Advanced Therapies Expanding Viral Vector Mfg 
Ascend Advanced Therapies, a CDMO of advanced therapy development and manufacturing, is expanding its GMP bioreactor capacity up to the 500-L scale and adding fill-finish capacity at its facility in Alachua, Florida. The company provides adeno-associated virus vector design and manufacturing.  

Existing space within its Alachua facility will feature new manufacturing suites and fill-finish capabilities. Bioreactors up to 500 L will be made available, with the goal of larger formats in the future. Additional space has been allocated to build out temperature-controlled GMP warehousing and process development labs with flexible operational space. Additionally, the company’s Munich, Germany, facility is bolstering GMP quality control testing, and analytical and process development capacity. The expansions are expected to run into 2025.   

Source: Ascend Advanced Therapies 

---

Verdot To Build New HQ & Mfg Facility for Downstream Bioprocessing Systems 
Verdot, a Riom, France-based company providing downstream bioprocessing systems and components, has purchased 11,000 square meters (2.7 acres) of land in Riom, France, for a new 4,200-square-meter (45,000-square feet) headquarters and manufacturing facility. Construction is expected to begin in the first quarter of 2025.  

The new facility will consolidate the company’s existing two facilities, create a Center of Excellence for bioprocessing manufacturing, research and development, and an applications laboratory. The facility will design, fabricate, and assemble bioprocessing purification products as well as create 150% additional manufacturing capacity for the company. The new facility is expected to open in early 2026.  

Source: Verdot 

---

Formulation Development/Drug Product Manufacturing 

Thermo Fisher Expands Oral Solid Dosage Ops at US Sites 
Thermo Fisher Scientific is expanding its oral solid dose (OSD) footprint at its sites in Cincinnati, Ohio, and Bend, Oregon, which double the Bend site’s existing footprint and continues a multi-year investment plan at its site in Cincinnati. 

In Cincinnati, the company has added dedicated flexible R&D space to support preclinical early development of OSD formulations. The Bend expansion is focused on R&D manufacturing and testing, including bench and pilot-scale spray drying, hot-melt extrusion, and dry granulation. These additions bolster capabilities at the company’s center of excellence for early development and advanced drug delivery, including solubility and bioavailability enhancement and digital modeling. Since 2021, the company has invested $22 million to expand its sites in Cincinnati and Bend.  

The expansions in Cincinnati and Bend build on the company’s continued investment in small-molecule OSD capabilities, including development and manufacturing services in Bourgoin, France; Manatí, Puerto Rico; Toronto, Canada; Whitby, Canada; and continuous manufacturing in Greenville, North Carolina.  

 Source: Thermo Fisher Scientific 

---

Ten23 Health Opens New Fill-Finish Facility 
Ten23 health, a Basel, Switzerland-based CDMO, has opened a new fill-finish facility in Visp, Switzerland. The new facility will provide capacity for clinical and commercial fill-finish of vials, syringes, and cartridges, in combination with quality control microbiology labs and related office space. 

The two additional sterile manufacturing lines include a large-scale commercial and clinical filling line for ready-to-use primary packaging for syringes, cartridges, and vials as well as a clinical-to-commercial bulk vial filling facility, including two larger-scale lyophilizers. The combined output is estimated to be 30 million to 70 million units. 

Source: ten23 health 

---

General 

Pace Life Sciences Acquires Catalent’s Center of Excellence for Small-Molecule Analytics 
Pace Life Sciences, a provider of contract services for formulation development, clinical-scale drug product manufacturing, and analytical testing, has acquired Catalent’s Center of Excellence for small-molecule analytical services in Research Triangle Park, North Carolina. 

Source: Pace Life Sciences